

Etna Biotech S.R.L.
Balance Sheet as at December 31, 2017

Particulars	Note No.	EUR- Thousands	
		As at December 31	
		2017	2016
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	1	86	93
Other Intangible Assets	1	1	5
Financial Assets:			
Other Financial Assets	2	1,502	607
		1,589	705
Current Assets:			
Financial Assets:			
Cash and Cash Equivalents	3	2,806	37
Total		4,395	742
EQUITY AND LIABILITIES:			
Equity:			
Equity Share Capital	4	90	90
Other Equity	5	67	256
		157	346
Non-Current Liabilities:			
Provisions	6	226	231
		226	231
Current Liabilities:			
Financial Liabilities:			
Trade Payables	7	26	16
Other Financial Liabilities	8	3,986	149
		4,012	165
Total		4,395	742
Notes to the Financial Statements	1 to 15		

Statement of Profit and Loss for the year ended December 31, 2017

Particulars	Note No.	EUR- Thousands	
		Year ended December 31	
		2017	2016
REVENUE:			
Revenue from Operations	9	386	301
Other Income	10	198	251
Total Revenue		584	552
EXPENSES:			
Employee Benefits Expense	11	339	330
Finance Costs	12	2	1
Depreciation, Amortisation and Impairment expenses	1	11	11
Other Expenses	13	421	165
Total Expenses		773	507
Profit for the year		(189)	45
OTHER COMPREHENSIVE INCOME:			
Other Comprehensive Income for the year, net of tax		-	-
Total Comprehensive Income for the year		(189)	45
Basic & Diluted Earning per Equity Share [EPS] [in Euro]	14	(210)	50
Notes to the Financial Statements	1 to 15		

For and on behalf of the Board


 Director

Etna Biotech S.R.L.

Statement of Change in Equity for the year ended December 31, 2017

a Equity Share Capital:	No. of Shares	EUR- Thousands
Equity Shares of EUR 100/- each, Issued, Subscribed and Fully Paid-up:		
As at December 31, 2015	900	90
Add [Less]: During the year	-	-
As at December 31, 2016	900	90
Add [Less]: During the year	-	-
As at December 31, 2017	900	90

	EUR- Thousands	
b Other Equity:	Retained Earnings	Total
As at December 31, 2015	211	211
Add: Profit for the year	45	45
As at December 31, 2016	256	256
Add: Profit for the year	(189)	(189)
As at December 31, 2017	67	67

For and on behalf of the Board


 Director

Etna Biotech S.R.L.
Notes to the Financial Statements

Note: 1: Property, Plant and Equipment :


	Property, Plant and Equipment			Intangible Assets
	<u>Plant and Equipment</u>	<u>Furniture and Fixtures</u>	<u>Total</u>	<u>Technical Know-how</u>
	EUR- Thousands			EUR- Thousands
Gross Block:				
As at December 31, 2015	5	235	240	5
Additions	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
As at December 31, 2016	5	235	240	5
Additions	-	-	-	-
Disposals	-	-	-	-
Other adjustments	(4)	14	10	4
As at December 31, 2017	1	249	250	9
Depreciation and Impairment:				
As at December 31, 2015	1	135	136	-
Charge for the year	-	11	11	-
Impairment for the year	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
As at December 31, 2016	1	146	147	-
Charge for the year	-	10	10	1
Impairment for the year	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	7	7	7
As at December 31, 2017	1	163	164	8
Net Block:				
As at December 31, 2016	4	89	93	5
As at December 31, 2017	-	86	86	1

91

Etna Biotech S.R.L.		
Notes to the Financial Statements		
	EUR- Thousands	
	As at December 31	
	2017	2016
Note: 2-Other Financial Assets:		
[Unsecured, Considered Good unless otherwise stated]		
Balances with Statutory Authorities	1,502	607
Total	1,502	607
Note: 3-Cash and Cash Equivalents:		
Balances with Banks	2,806	37
Total	2,806	37
Note: 4-Equity Share Capital:		
Authorised:		
900 [as at December 31, 2016: 900] Equity Shares of € 100/- each	90	90
	90	90
Issued, Subscribed and Fully Paid-up Equity Shares:		
900 [as at December 31, 2016: 900] Equity Shares of € 100/- each	90	90
	90	90
A The reconciliation of the number of Shares outstanding as at December 31, 2017 and 2016 is as under:		
Number of shares at the beginning	900	900
Add: Shares issued during the year	-	-
Less: Shares redeemed during the year	-	-
Number of shares at the end	900	900
B The Company has only equity shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts.		
C Equity shares of € 100/- each, fully paid, held by Holding Company, Zydus Worldwide DMCC incorporated in Dubai [Refer Note 15] which is a subsidiary company of Cadila Healthcare Limited, the ultimate holding company, a company incorporated in India.		
Number of Shares	900	900
% to total share holding	100%	100%
Note: 5-Other Equity:		
Retained Earnings:		
Balance as per last Balance Sheet	256	211
Add: Profit for the year	(189)	45
Total	67	256
Note: 6-Provisions:		
Provision for Employee Benefits	226	216
Other long term provisions	-	15
Total	226	231
Note: 7-Trade Payables:		
Others	26	16
Total	26	16
Note: 8-Other Financial Liabilities:		
Provision for Expenses	190	149
Payable to Statutory Authorities	3,796	-
Total	3,986	149

π

Etna Biotech S.R.L.
Notes to the Financial Statements

	EUR- Thousands	
	Year ended December 31	
	2017	2016
Note: 9-Revenue from Operations:		
Sale of Services	386	301
Total	386	301
Note: 10-Other Income:		
Other Non-operating Income	198	251
Total	198	251
Note: 11-Employee Benefits Expense:		
Salaries and wages	243	239
Contribution to provident and other funds	71	84
Staff welfare expenses	25	7
Total	339	330
Note: 12-Finance Cost:		
Bank commission & charges	2	1
Total	2	1
Note: 13-Other Expenses:		
Research Materials	45	47
Analytical Expenses	92	-
Rent	37	37
Repairs to Others	6	-
Traveling Expenses	12	4
Legal and Professional Fees	17	11
Bad Debts:		
Bad debts written off	50	-
Miscellaneous Expenses	162	66
Total	421	165
Note: 14-Calculation of Earnings per Equity Share [EPS]:		
The numerators and denominators used to calculate the basic and diluted EPS are as follows:		
A Profit attributable to Shareholders	(189)	45
B Basic and weighted average number of Equity shares outstanding during the year	900	900
	EUR	
C Nominal value of equity share	100	100
D Basic & Diluted EPS	(210)	50
Note: 15		
Pursuant to the Share Purchase Agreement ["SPA"] entered into by the Parent Company [Zydus International Private Limited, Ireland] on March 24, 2017 with Zydus Worldwide DMCC [Dubai] a 100% subsidiary of the ultimate Parent Company [Cadila Healthcare Limited, India], Zydus Worldwide DMCC [Dubai] had acquired 100% of the share capital of Etna Biotech S.R.L. for Cash Consideration. Pursuant to this, Etna Biotech S.R.L. has become direct subsidiary of Zydus Worldwide DMCC [Dubai].		
Signatures to Significant Accounting Policies and Notes 1 to 15 to the Financial Statements		
For and on behalf of the Board		
 Director		

Etna Biotech S.R.L.
Cash Flow Statement for the year ended December 31, 2017

Particulars	EUR- Thousands	
	Year ended December 31	
	2017	2016
A Cash flows from operating activities:		
Profit before tax	(189)	45
Adjustments for:		
Depreciation, Impairment and Amortisation expenses	11	11
Bad debts written off	50	-
Provisions for employee benefits	10	14
Other Provisions	(15)	-
Total	56	25
Operating profit before working capital changes	(133)	70
Adjustments for:		
[Increase] in trade receivables	(50)	-
[Increase] in other financial asset	(895)	(96)
Increase/ [Decrease] in trade payables	10	(28)
Increase in other current liabilities	3,837	23
[Decrease] in other long term liabilities	-	(214)
Total	2,902	(315)
Net cash used in operating activities	2,769	(245)
B Cash flows from investing activities:		
Net cash used [from] in investing activities	-	-
C Cash flows from financing activities:		
Net cash used [from] in financing activities	-	-
Net Increase/ [Decrease] in cash and cash equivalents	2,769	(245)
Cash and cash equivalents at the beginning of the year	37	282
Cash and cash equivalents at the end of the year	2,806	37

Notes to the Cash Flow Statement

- 1 All figures in brackets are outflows.
- 2 Previous year's figures have been regrouped wherever necessary.

For and on behalf of the Board


 Director